IRAK4 (Interleukin-1 Receptor-Associated Kinase 4) is a serine/threonine kinase that plays an essential role in Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways. Located on chromosome 15q15.4, IRAK4 is the most upstream kinase in the MyD88-dependent signaling cascade, making it a critical regulator of innate immune responses. Dysregulated IRAK4 signaling contributes to chronic neuroinflammation in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS).
| IRAK4 - Interleukin-1 Receptor-Associated Kinase 4 |
|---|
| Gene Symbol | IRAK4 |
| Full Name | Interleukin-1 Receptor-Associated Kinase 4 |
| Chromosome | 15q15.4 |
| NCBI Gene ID | 51135 |
| OMIM | 606883 |
| Ensembl ID | ENSG00000163428 |
| UniProt ID |
| Q9NR27 |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, ALS, Immunodeficiency |
IRAK4 is the key upstream kinase in the MyD88-dependent TLR/IL-1R signaling pathway. Unlike other IRAK family members, IRAK4 is essential for signaling through all MyD88-dependent TLRs and IL-1R family members. Upon ligand binding, IRAK4 is recruited to the receptor complex where it undergoes autophosphorylation and then phosphorylates downstream IRAK1, leading to activation of NF-κB and MAPK signaling pathways.
In the central nervous system, IRAK4-mediated signaling drives neuroinflammation through activation of microglia and astrocytes. This makes IRAK4 a critical therapeutic target for neurodegenerative diseases where chronic neuroinflammation drives disease progression.
¶ Gene Structure and Function
IRAK4 encodes a 460-amino acid serine/threonine kinase with the following structural features:
- N-terminal Death Domain (DD): Mediates interactions with MyD88 adaptor protein
- Intermediate domain: Connects DD to kinase domain
- Kinase Domain (KD): Catalytic domain with serine/threonine kinase activity (active, unlike IRAK2/3)
IRAK4 functions as the master regulator of innate immune signaling:
- TLR Signaling: Essential for all MyD88-dependent TLRs (TLR1/2/4/5/6/7/8/9)
- IL-1R Signaling: Critical for IL-1R1 and IL-18R signaling
- Signal Initiation: Most upstream kinase in the IRAK cascade
- Kinase Activity: Catalytically active, phosphorylates IRAK1
- NF-κB Activation: Triggers IKK complex activation
- MAPK Activation: Activates JNK, p38, and ERK pathways
IRAK4 has unique features among IRAK family members:
- Active kinase: Unlike IRAK2 and IRAK3, IRAK4 has demonstrable kinase activity
- Essential for signaling: Knockout abolishes TLR/IL-1R signaling
- Therapeutic target: Considered a "druggable" kinase target
IRAK4 is expressed in immune cells and various tissues:
- High expression: Peripheral blood leukocytes, spleen, thymus
- Moderate expression: Lung, liver, heart, brain
- Low expression: Most other tissues
In the central nervous system:
- Microglia: High expression, particularly in activated states
- Astrocytes: Present, upregulated during inflammation
- Neurons: Low basal expression, inducible under stress
- Oligodendrocytes: Lower expression
Expression is induced by:
- Pro-inflammatory cytokines (IL-1β, TNF-α)
- TLR ligands (LPS, CpG DNA)
- Cellular stress
IRAK4 contributes to AD pathogenesis through neuroinflammatory mechanisms:
- Microglial Activation: IRAK4 is essential for TLR-mediated microglial activation
- Aβ-Induced Inflammation: Amyloid-β triggers IRAK4-dependent inflammatory responses
- Chronic Neuroinflammation: Sustained IRAK4 signaling promotes ongoing inflammation
- Synaptic Dysfunction: Inflammatory mediators from IRAK4 pathways impair synaptic function
- Tau Pathology: IRAK4-mediated signaling can influence tau phosphorylation
IRAK4 signaling is implicated in PD:
- Microglial Activation: α-Synuclein activates TLR/IRAK4 pathways in microglia
- Neuroinflammation: Substantia nigra shows enhanced IRAK4 activity in PD
- Dopaminergic Neuron Vulnerability: Inflammatory signaling contributes to neuronal death
- LRRK2 Interaction: May cooperate with LRRK2 in inflammatory responses
- Motor Neuron Degeneration: IRAK4 activation in microglia promotes motor neuron injury
- Inflammatory Responses: Contributes to toxic microglial phenotype
- Therapeutic Target: IRAK4 inhibitors being explored for ALS
IRAK4 deficiency in humans causes:
- Immunodeficiency 67 (IMD67): Recurrent infections, particularly pyogenic bacteria
- Impaired TLR Signaling: Severely reduced responses to TLR ligands
- Live Attenuated Vaccine Sensitivity: Risk from certain vaccines
IRAK4 is considered a promising therapeutic target:
-
Small Molecule Inhibitors:
- PF-06426779 (Pfizer)
- KY-05014 and derivatives
-razole-based inhibitors
-
Advantages of IRAK4 Inhibition:
- Upstream position in pathway
- Catalytically active (easier to target)
- Broader anti-inflammatory effects than IRAK1
-
Clinical Trials:
- IRAK4 inhibitors in development for autoimmune diseases
- Potential for repurposing in neurodegeneration
- Immune suppression risk with systemic inhibition
- Need for brain-penetrant compounds
- Balancing anti-inflammatory vs. beneficial immune functions
graph TD
A[TLR/IL-1R Ligand] --> B[Receptor Complex] -->
B --> C[MyD88)
C --> D[IRAK4)
D --> E[IRAK1)
E --> F[TRAF6)
F --> G[NF-κB Activation] -->
F --> H[MAPK Activation] -->
G --> I[Inflammatory Genes] -->
H --> J[Cell Stress Response] -->
I --> K[Neuroinflammation)
K --> L[Neurodegeneration]
- IraK4-/- mice: Viable but highly susceptible to bacterial infections
- Impaired inflammatory responses to TLR/IL-1 ligands
- Reduced cytokine production
- IRAK4 inhibitors: Reduce neuroinflammation in mouse models
- Combination therapy: IRAK4 + IRAK1 inhibition more effective
The study of Irak4 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Suzuki N, et al. (2002). "IRAK4 is essential for Toll-like receptor-induced activation of NF-κB." Nature. PMID:12475897
- Kawagoe T, et al. (2008). "Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK4." Nature. PMID:18928436
- Kim TW, et al. (2007). "A critical role for IRAK4 kinase activity in Toll-like receptor-mediated innate immunity." Journal of Experimental Medicine. PMID:17227916
- Stasny M, et al. (2018). "IRAK4 deficiency with recurrent infections." Journal of Clinical Immunology. PMID:29464569
- Deng Y, et al. (2020). "IRAK4 in neuroinflammation and neurodegenerative diseases." Frontiers in Cellular Neuroscience. PMID:32082193